Ontology highlight
ABSTRACT:
SUBMITTER: Li X
PROVIDER: S-EPMC4747386 | biostudies-literature | 2015 Dec
REPOSITORIES: biostudies-literature
Li Xiangyan X Wu Jason Boyang JB Chung Leland W K LW Huang Wen-Chin WC
Oncotarget 20151201 38
Mutant p53 proteins (mutant p53s) have oncogenic gain-of-function properties correlated with tumor grade, castration resistance, and prostate cancer (PCa) tumor recurrence. Docetaxel is a standard first-line treatment for metastatic castration-resistant PCa (mCRPC) after the failure of hormone therapy. However, most mCRPC patients who receive docetaxel experience only transient benefits and rapidly develop incurable drug resistance, which is closely correlated with the p53 mutation status. Mutan ...[more]